Andrew F Cheng

US Patent:

8329447, Dec 11, 2012

Filed:

Dec 9, 2009

Appl. No.:

12/634504

Inventors:

Yang Liu - Mountain View CA, US
Rosa R. Yu - Sunnyvale CA, US
Andrew Cheng - San Jose CA, US
Qing Xia - Santa Clara CA, US
Qiang Xu - Cupertino CA, US

Assignee:

Osel, Inc. - Santa Clara CA

International Classification:

C12N 1/20
A01N 63/00

US Classification:

4352529, 424 9345

Abstract:

The invention provides a naturally occurring strain of with advantageous characteristics. The strain colonizes mucosal surfaces, particularly vaginal surfaces. The strain is also capable of rapid growth in a number of conditions and is highly viable after desiccation. Moreover, the strain is capable of preventing and reducing pathogenic infection of vaginal mucosa.

US Patent:

57064539, Jan 6, 1998

Filed:

Feb 6, 1995

Appl. No.:

8/384016

Inventors:

Andrew Y. Cheng - San Jose CA

International Classification:

G06F 1500

US Classification:

395347

Abstract:

A configuration management system which generates and updates its own real-time dynamic database for representing a system configuration. The configuration management system includes an user interface for receiving user input of free-hand graphic drawings representing system configuration changes. The configuration management system further includes an interactive graphic interpretive and linking actuator which employs the user input of free-hand graphic drawings representing the system configuration changes for linking to sections of the database corresponding to the user input of configuration changes and updating data stored therein thus representing a new system configuration updated by the user input of the configuration changes. The user interface future includes a dialog box for receiving system parameters relating to the user input of free-hand graphic drawings representing the system configuration changes. The interactive graphic interpretive and linking actuator further employs the system parameters received from the dialog box for updating the database.

US Patent:

20210213078, Jul 15, 2021

Filed:

Mar 23, 2021

Appl. No.:

17/210078

Inventors:

- San Francisco CA, US
Colleen CUTCLIFFE - Menlo Park CA, US
Orville KOLTERMAN - San Francisco CA, US
Fanny PERRAUDEAU - San Francisco CA, US
James BULLARD - San Francisco CA, US
Paul MCMURDIE - San Francisco CA, US
Andrew CHENG - San Francisco CA, US
Marcus SCHICKLBERGER - San Francisco CA, US
Nicholas JUSTICE - San Francisco CA, US

International Classification:

A61K 35/747
A61K 9/00
A61K 35/742
A61K 35/741
A61K 35/745
A61K 35/744
A61K 31/155
A61P 3/10

Abstract:

Administering a composition comprising at least one mucin-regulating and at least one butyrate-producing microbe can provide a therapeutic effect for subjects having prediabetes or type 2 diabetes. Therapeutic effects can include a reduction in hemoglobin A1C levels, a reduction in glucose area under the curve after a meal tolerance test, or a reduction in the fasting glucose level.

US Patent:

20210205374, Jul 8, 2021

Filed:

Jan 15, 2021

Appl. No.:

17/150501

Inventors:

- San Francisco CA, US
Colleen CUTCLIFFE - Menlo Park CA, US
James H. BULLARD - San Francisco CA, US
Nicholas JUSTICE - San Francisco CA, US
Jessica GINES - San Francisco CA, US
Surabhi TYAGI - San Francisco CA, US
Marcus F. SCHICKLBERGER - Richmond CA, US
Andrew T. CHENG - San Mateo CA, US
Paul MCMURDIE - San Francisco CA, US
Christian SIEBER - San Francisco CA, US

International Classification:

A61K 35/74
A61P 37/06
A61K 38/28

Abstract:

The disclosure provides compositions and methods for therapeutic administration of the compositions to treat comorbidities associated with gut dysbiosis. The disclosure also provides compositions and methods for increasing engraftment of administered microbes. The disclosure also provides methods for stool sample collection.

US Patent:

20160000079, Jan 7, 2016

Filed:

Feb 19, 2014

Appl. No.:

14/768468

Inventors:

Roger LININGTON - , US
Havva Fitnat GURCAN - Santa Cruz CA, US
Kelly Corbus PEACH - Santa Cruz CA, US
Andrew T. CHENG - Santa Cruz CA, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

International Classification:

A01N 43/84
C07D 417/06
A61K 31/538
A61L 31/08
A61K 31/541
C07D 265/36
A61L 31/16

Abstract:

Novel compounds and the novel use a class of previously identified small molecules for the inhibition of biofilm formation. Inhibition of biofilm formation can play a very important role in contributing to pathogenicity. Bacteria in the biofilm state have been shown to be 10-10,000-fold less susceptible to antibiotic treatment. Estimations made by the Centers for Disease Control (CDC) and the National Institutes of Health (NIH) attribute 65% to 80% of human infections as biofilm mediated. Consequently, biofilm formation is often responsible for chronic infections due to bacterial persistence despite antibiotic treatment.